Conclusion
Our study revealed several chromosomal mutations and the existence of immunosuppression via a PD-1/PD-L1 pathway in the metastatic ITTC. Further clinical studies with larger numbers of patients with metastatic ITTC will be needed to obtain the robust evidence required to recommend the use of an ICI for metastatic ITTC treatment.